Please assess the completion status of the following clinical trial:

Trial Title: DEB-TACE for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older, inclusive~* Diagnosis of HCC~* Meets UCSF criteria: a single lesion less than or equal to 6.5 cm in diameter or 2-3 lesions less than or equal to 4.5 cm with total tumor diameter less than or equal to 8 cm.~* No portal invasion or extrahepatic spread on imaging.~* Child-Pugh Class A or B.~* No previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy).~* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* A discrete hepatic artery feeding the tumor with diameter of the vessels equal to or greater than 1.5 mm.~Exclusion Criteria:~* Bilirubin levels greater than 3 mg/dl~* AST or ALT greater than 5 times upper limit of normal or greater than 250 U/l.~* Advanced tumoral disease (vascular invasion or extrahepatic spread, portal vein thrombosis of bland or malignant origin), or diffuse HCC, defined as 50% liver involvement).~* Contraindications for doxorubicin administration.~* Subject has a known history contraindicating contrast dye or iodine that cannot be safely controlled via antihistamine, steroids, or with any other agent.~* Unable or unwilling to provide informed consent.~* Vessels providing flow to the tumor that are less than 1.5 mm in diameter.~* Women who are pregnant or breast feeding.~* Women of childbearing potential who are not using an acceptable method of birth control (e.g., pill, patch, IUD, ring, condom, sponge, foam).~* Portal vein thrombosis of bland or malignant origin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DEB-TACE: Standard Endhole Catheter (Type: ACTIVE_COMPARATOR): Subjects will undergo DEB-TACE using a standard endhole catheter.
- DEB-TACE: Surefire Infusion System (Type: ACTIVE_COMPARATOR): Subjects will undergo DEB-TACE using the Surefire Infusion System.

Based on this trial design, predict the completion outcome and termination type (if applicable).